Business Segments · Goodwill
Pharmaceutical and Specialty Solutions — Goodwill
Cardinal Health Pharmaceutical and Specialty Solutions — Goodwill decreased by 2.0% to $9.67B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $7.74B to $9.67B.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ2 2022
Last reportedQ1 2026
Rolls up toGoodwill
How to read this metric
An increase indicates recent acquisitions, while a decrease may signal impairment or divestiture.
Detailed definition
Represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinat...
Peer comparison
Common across large-cap healthcare distributors like Cencora and McKesson following M&A activity.
Metric ID:
cah_segment_pharmaceutical_and_specialty_solutions_goodwillHistorical Data
11 periods
| Q2 '22 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.79B | $2.76B | $3.62B | $3.56B | $3.56B | $4.32B | $7.74B | $7.94B | $7.97B | $9.86B | $9.67B |
| QoQ Change | — | -0.9% | +31.0% | -1.7% | +0.0% | +21.5% | +79.2% | +2.7% | +0.3% | +23.8% | -2.0% |
| YoY Change | — | -0.9% | — | +28.7% | — | — | +113.8% | +123.4% | +124.1% | +128.4% | +25.0% |
Range$2.76B – $9.86B
CAGR+64.5%
Avg YoY Growth+77.5%
Median YoY Growth+113.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cardinal Health's pharmaceutical and specialty solutions — goodwill?
- Cardinal Health (CAH) reported pharmaceutical and specialty solutions — goodwill of $9.67B in Q1 2026.
- How has Cardinal Health's pharmaceutical and specialty solutions — goodwill changed year-over-year?
- Cardinal Health's pharmaceutical and specialty solutions — goodwill increased by 25.0% year-over-year, from $7.74B to $9.67B.
- What does pharmaceutical and specialty solutions — goodwill mean?
- The total value of intangible assets like brand and customer loyalty recorded from past acquisitions in the pharmaceutical segment.